LATEST

Signum Biosciences Receives $3.0M Phase IIB SBIR Grant

Signum Biosciences Receives $3.0M Phase IIB SBIR Grant for the Development of SIG1451, A Novel Atopic Dermatitis Therapeutic

http://www.prnewswire.com/news-releases/signum-biosciences-receives-30m-phase-iib-sbir-grant-for-the-development-of-sig1451-a-novel-therapeutic-for-atopic-dermatitis-300407911.html